An Interventional Open-Label, Single-Dose, 4-Treatment, 4-Period Crossover Study to Evaluate the Relative Bioavailability of CTB and AVI Administered Via Various Tablets or Capsule Formulations of PF-07612577 (PF-06264006 [CTB] - PF-07338233 [AVP]) and the Effect of Food on the Bioavailability of CTB and AVI Administered Via Tablets in Healthy Adult Participants
Latest Information Update: 14 Oct 2024
At a glance
- Drugs PF 07612577 (Primary) ; Avibactam; Ceftibuten
- Indications Urinary tract infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 08 Oct 2024 Planned End Date changed from 27 Sep 2024 to 11 Oct 2024.
- 08 Oct 2024 Planned primary completion date changed from 27 Sep 2024 to 11 Oct 2024.
- 08 Oct 2024 Status changed from recruiting to active, no longer recruiting.